Skip to main content

Advertisement

Table 1 Basic characteristics of patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL) in distinct ABO blood type groups

From: Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study

Characteristic Total (cases) Blood four-type group [cases (%)] P Blood two-type group [cases (%)] P
O A B AB O Non-O
Total 697 255 195 188 59   255 442  
Age (years)       0.313    0.722
 ≤60 597 220 (86.3) 162 (83.1) 167 (88.8) 48 (81.4)   220 (86.3) 377 (85.3)  
 >60 100 35 (13.7) 33 (16.9) 21 (11.2) 11 (18.6)   35 (13.7) 65 (14.7)  
Gender       0.854    0.730
 Male 492 178 (69.8) 137 (70.3) 137 (72.9) 40 (67.8)   178 (69.8) 314 (71.0)  
 Female 205 77 (30.2) 58 (29.7) 51 (27.1) 19 (32.2)   77 (30.2) 128 (29.0)  
ECOG PS       0.960    0.911
 0–1 680 249 (97.6) 190 (97.4) 184 (97.9) 57 (96.6)   249 (97.6) 431 (97.5)  
 ≥2 17 6 (2.4) 5 (2.6) 4 (2.1) 2 (3.4)   6 (2.4) 11 (2.5)  
B symptoms       0.295    0.133
 Yes 324 109 (42.7) 101 (51.8) 86 (45.7) 28 (47.5)   109 (42.7) 215 (48.6)  
 No 373 146 (57.3) 94 (48.2) 102 (54.3) 31 (52.5)   146 (57.3) 227 (51.4)  
LDH (U/L)       0.596    0.602
 >245 194 68 (26.7) 53 (27.2) 59 (31.4) 14 (23.7)   68 (26.7) 126 (28.5)  
 ≤245 503 187 (73.3) 142 (72.8) 129 (68.6) 45 (76.3)   187 (73.3) 316 (71.5)  
Tumor size (cm)       0.399    0.953
 ≥5 65 24 (9.4) 21 (10.8) 18 (9.6) 2 (3.4)   24 (9.4) 41 (9.3)  
 <5 632 231 (90.6) 174 (89.2) 170 (90.4) 57 (96.6)   231 (90.6) 401 (90.7)  
Extranodal sites ≥2       0.685    0.966
 Yes 77 28 (11.0) 22 (11.3) 18 (9.6) 9 (15.3)   28 (11.0) 49 (11.1)  
 No 620 227 (89.0) 173 (88.7) 170 (90.4) 50 (84.7)   227 (89.0) 393 (88.9)  
Regional LN involvement       0.605    0.239
 Yes 171 69 (27.1) 42 (21.5) 46 (24.5) 14 (23.7)   69 (27.1) 102 (23.1)  
 No 526 186 (72.9) 153 (78.5) 142 (75.5) 45 (76.3)   186 (72.9) 340 (76.9)  
EBV-DNA (copies/mL)a       0.435    0.829
 <1530 85 31 (50.8) 20 (46.5) 22 (44.9) 12 (66.7)   31 (50.8) 54 (49.1)  
 ≥1530 86 30 (49.2) 23 (53.5) 27 (55.1) 6 (33.3)   30 (49.2) 56 (50.9)  
CRP (mg/L)b       0.197    0.038
 ≤10 128 55 (61.1) 26 (50.0) 36 (46.3) 11 (42.1)   55 (61.1) 73 (47.1)  
 >10 100 35 (38.9) 26 (50.0) 31 (53.7) 8 (57.9)   35 (38.9) 65 (52.9)  
Ann Arbor stage       0.749    0.894
 I/II 619 227 (89.0) 173 (88.7) 169 (89.9) 50 (84.7)   227 (89.0) 392 (88.7)  
 III/IV 78 28 (11.0) 22 (11.3) 19 (10.1) 9 (15.3)   28 (11.0) 50 (11.3)  
IPI score       0.763    0.421
 0–1 597 222 (87.1) 164 (84.1) 162 (86.2) 49 (83.1)   222 (87.1) 375 (84.8)  
 2–5 100 33 (12.9) 31 (15.9) 26 (13.8) 10 (16.9)   33 (12.9) 67 (15.2)  
KPI score       0.974    0.984
 0–1 478 175 (68.6) 133 (68.2) 128 (68.1) 42 (71.2)   175 (68.6) 303 (68.6)  
 2–4 219 80 (31.4) 62 (31.8) 60 (31.9) 17 (28.8)   80 (31.4) 139 (31.4)  
  1. ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, LN lymph node, EBV Epstein–Barr virus, CRP C-reactive protein, IPI International Prognostic Index, KPI Korean Prognostic Index
  2. aData of EBV-DNA copy number were available for 171 patients, and the median value was 1530 copies/mL
  3. bData of serum CRP levels were available for 228 patients, and the CRP level >10 mg/L was used as the cutoff value